High doses of a drug widely used in the hormonal treatment of affections such as extreme hair growth, early puberty, prostate cancers are linked to an increased risk of meningioma - the most common fate of benign brain tumor, according to a study university carried out by Bristol on Additional 8 Tens of Millions of individuals. The study is published today in Scientific Stories [Friday 4 Feb 2022].

Generally with slow growth, meningiomas are benign tumors, which are often accidentally revealed by imaging, but can cause significant disability due to compression or compression of the brain, nerves and adjacent vessels and pressure effects in a fixed cranial vault. Recent studies have reported an affiliation between the growth of meningiomas and hormonal treatments, in particular prolonged and high dose of the cyproterone acetate drug (CPA).

High doses of cyproterone acetate (> 50 mg/day) are generally prescribed to male individuals with a most inoperable prostate cancers, a passion that causes Too much growth known as hirsutism, or transsexual transsexual hormone therapy.

Lower doses (2 to 10 mg/day) of the drug are generally used in affiliation with estradiol to treat alopecia associated with androgens or female seborrhea. Given the widespread use of the drug, researchers from the universities of Bristol, Cambridge and the National University of Singapore led a systematic review and a meta-analysis using four studies including a sample of 8,132,348 people, in order to assess the evidence of the association between cyproterone acetate and the incidence of meningiomas.

The sample included 165,988 patients who were identified as taking cyproterone acetate at variable doses . Using this data, the team analyzed the occurrence of meningioma in patients using cyproterone acetate in high doses or low doses and has found a significant association between the use of high doses and an increased risk of meningioma. However, this affiliation was not found with low doses. Keng Siang Lee, medical student and principal author of the study of the Bristol Professional Medical University of the University of Bristol, said: "The result in meningiomes is controversial, but there is solid evidence suggesting a plausible role of sex hormones in the appearance of meningioma. We know that he has a predilection for women, especially after puberty. In addition, fluctuations in the growth of meningioma during the menstrual cycle, pregnancy and breastfeeding have also been well documented. We are also aware of the well -characterized distribution of progesterone, estrogens and androgens receptors in certain meningiomas located at the base of the skull.

“In light of these results, the prescription of high -dose cyproterone acetate, in particular for the indications not indicated on the label, must be considered with caution. In addition, we suggest that plan screening and monitoring of brain MRI proposed to people to which cyproterone acetate has been prescribed are probably a reasonable solution. Clinical consideration if administered in high doses for long periods.

“However, our study highlights the current limited evidence on the risk of intracranial meningioma associated with low -dose cyproterone acetate. We still do not know if cyproterone acetate below a certain threshold can be completely safe in terms of risk of meningioma. The results obtained here suggest the need to continue clinical research on intracranial meningioma associated with cyproterone acetate. »»

Source Citizen Side: https://www.citizenside.fr/Medicament-hormonal-risque-accru-tumeur-cerebrale-benigne-fortes-doses/?utm_source=cpp